Immix Biopharma prices $15M public offering of 5.5M shares at $2.71/share

Immix Biopharma, Inc.

Offering of 5,535,055 shares at $2.71 per share; gross proceeds ~$15M before expenses.
Underwriter granted 30-day over-allotment option for up to 783,970 additional shares.
Net proceeds to fund NXC-201 clinical trials, working capital, and general corporate purposes.
Closing expected February 8, 2024; subject to customary conditions.
Directors and officers subject to 90-day lock-up expiring May 8, 2024.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Immix Biopharma, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at $15 million (effective 2024-02-05).

Action: entry
Agreement: underwriting
Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
Value: $15 million
Effective: 2024-02-05

Exact text from the filing

On February 5, 2024, Immix Biopharma, Inc. (the “Company”) entered into an Underwriting Agreement (the “Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 5,535,055 shares (“Shares”) of common stock of the Company (“Common Stock”).

View on SEC.gov

Browse all material agreements →

Immix Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-005043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.